Curtis T. Keith
Directeur/Membre du Conseil chez Translational Development Acquisition Corp.
Profil
Curtis T.
Keith was the founder of CombinatoRx, Inc. which was founded in 2000, where he held the title of Senior Vice President-Research from 2000 to 2008.
Currently, he is a Director at Translational Development Acquisition Corp.
Dr. Keith's education history includes a graduate and doctorate degree from Harvard University and an undergraduate degree from McGill University.
Postes actifs de Curtis T. Keith
| Sociétés | Poste | Début |
|---|---|---|
Translational Development Acquisition Corp.
 Translational Development Acquisition Corp. Financial ConglomeratesFinance Translational Development Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 19, 2022 and is headquartered in New York, NY. | Directeur/Membre du Conseil | - |
Anciens postes connus de Curtis T. Keith
| Sociétés | Poste | Fin |
|---|---|---|
CombinatoRx, Inc.
 CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Fondateur | 07/02/2008 |
Formation de Curtis T. Keith
| Harvard University | Doctorate Degree |
| McGill University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Health Technology |
Translational Development Acquisition Corp.
Translational Development Acquisition Corp. Financial ConglomeratesFinance Translational Development Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 19, 2022 and is headquartered in New York, NY. | Finance |
